Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
One hundred years after the First World War began, British taxpayers are still servicing the loans taken out to finance the conflict.
FIFA have deleted a video they published showing Crimea as part of Russia in a promotional video for the 2018 World Cup
A cat who survived a brutal beating because he looks like Hitler has battled back from the brink of death to make a full recovery.